Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 14/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 0.71 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520819 | 0.86 | HDAC1 (0.72) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| SCHEMBL1520815 | 0.86 | HDAC1 (0.72) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| SCHEMBL13859920 | 0.86 | HDAC1 (0.72) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| SCHEMBL1521164 | 0.85 | HDAC1 (0.70) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| SCHEMBL13465162 | 0.85 | HDAC1 (0.70) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| SCHEMBL1521160 | 0.85 | HDAC1 (0.70) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| SCHEMBL1521000 | 0.84 | HDAC1 (0.60) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| SCHEMBL1520997 | 0.84 | HDAC1 (0.60) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| Trichostatin SCHEMBL16380793 | 0.83 | HDAC1 (1.00) | HDAC1HDAC4HDAC3HDAC2HDAC8 | |
| Trichostatin SCHEMBL675951 | 0.83 | HDAC1 (1.00) | HDAC1HDAC4HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | HDAC1 1/4885HDAC4 7/4885HDAC3 2/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | HDAC1 5/4885HDAC4 27/4885HDAC3 3/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | HDAC1 9/4885HDAC4 30/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.